Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023

Rhea-AI Summary

Altimmune, Inc. announced that Dr. Stephen A. Harrison will present results from the 12-week Phase 1b and subsequent extension trials of pemvidutide for non-alcoholic fatty liver disease (NAFLD) at the NASH-TAG Conference on January 7, 2023. Pemvidutide, a dual receptor agonist for obesity and NASH, showed significant reductions in liver fat and body weight. The company is focused on the development of innovative therapeutic solutions targeting liver diseases and obesity, with pemvidutide being a key candidate.

Positive

• Pemvidutide showed significant reductions in liver fat and body weight.
• The presentation at the NASH-TAG Conference highlights the progress in clinical development.

Negative

• None.

GAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Chairman and Co-Founder, Pinnacle Clinical Research and Summit Clinical Research, will deliver an oral presentation of the results of Altimmune’s recently completed 12-week Phase 1b and 12-week extension trials of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD) at the NASH-TAG Conference, which will be held in Park City, UT on January 6-7, 2023. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH. Details for the oral presentation are as follows:

Title:	Pemvidutide, a Balanced GLP-1/Glucagon Dual Receptor Agonist, Significantly Reduces Liver Fat, Non-invasive Markers of Fibroinflammation, and Body Weight in Patients with Non-alcoholic Fatty Liver Disease: Results of a Multicenter, Randomized, Double-blind, Placebo-controlled Trial
Presenter:	Stephen Harrison, M.D., Chairman and Co-Founder of Pinnacle Clinical Research and Summit Clinical Research in San Antonio, TX
Date/Time:	Saturday, January 7, 2023, at 10:30 am Mountain Standard Time

A copy of the presentation will be accessible on the Events section of the Altimmune website.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Investor & Media Contacts:

Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com

FAQ

What are the results of the pemvidutide trials presented by Altimmune?

The trials showed significant reductions in liver fat, non-invasive markers of fibroinflammation, and body weight in NAFLD patients.

When is Altimmune's pemvidutide presentation at the NASH-TAG Conference?

The presentation is scheduled for January 7, 2023, at 10:30 am Mountain Standard Time.

What is pemvidutide developed by Altimmune used for?

Pemvidutide is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH).

What is the significance of the Phase 1b trial results for pemvidutide?

The Phase 1b trial results indicate potential for pemvidutide in effectively treating NAFLD, which could impact its market potential significantly.